Early biologic response patterns in plaque psoriasis revealed faster remission with anti-IL-17AF and underscored the need for tailored treatment strategies.

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to find out why I rate PTGX is a Buy.

Bristol Myers BMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint. Sotyktu is an oral, selective tyrosine ...

The PASI score grades the amount of surface area on each body region that is covered by psoriasis plaques and the severity of plaques for their redness, thickness and scaliness.3 PASI 90 ...

The co-primary efficacy objectives of this study are the proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) and the proportion of ...

At Week 24, nearly half of patients treated with icotrokinra achieved completely clear skin - 46% reached IGA 0 and 40% reached PASI 100. 1 Nearly two-thirds (65%) of patients treated with once daily ...

Across both clinical trials and timepoints, significantly more Sotyktu-treated patients achieved a sPGA score of 0/1, PASI 75 response and PASI 90 response.

Acelyrin's izokibep showed mixed results in trials, leading to workforce cuts and a shift in focus to lonigutamab for thyroid eye disease. Click for more on SLRN.

The phase 3 success pads the IL-23 blocker's case as J&J prepares to prove its worth against BMS' oral psoriasis treatment Sotyktu.

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...